Cancers (Jan 2023)

Targeting the Hedgehog Pathway in Rhabdomyosarcoma

  • Patricia Zarzosa,
  • Lia Garcia-Gilabert,
  • Raquel Hladun,
  • Gabriela Guillén,
  • Gabriel Gallo-Oller,
  • Guillem Pons,
  • Julia Sansa-Girona,
  • Miguel F. Segura,
  • Josep Sánchez de Toledo,
  • Lucas Moreno,
  • Soledad Gallego,
  • Josep Roma

DOI
https://doi.org/10.3390/cancers15030727
Journal volume & issue
Vol. 15, no. 3
p. 727

Abstract

Read online

Aberrant activation of the Hedgehog (Hh) signalling pathway is known to play an oncogenic role in a wide range of cancers; in the particular case of rhabdomyosarcoma, this pathway has been demonstrated to be an important player for both oncogenesis and cancer progression. In this review, after a brief description of the pathway and the characteristics of its molecular components, we describe, in detail, the main activation mechanisms that have been found in cancer, including ligand-dependent, ligand-independent and non-canonical activation. In this context, the most studied inhibitors, i.e., SMO inhibitors, have shown encouraging results for the treatment of basal cell carcinoma and medulloblastoma, both tumour types often associated with mutations that lead to the activation of the pathway. Conversely, SMO inhibitors have not fulfilled expectations in tumours—among them sarcomas—mostly associated with ligand-dependent Hh pathway activation. Despite the controversy existing regarding the results obtained with SMO inhibitors in these types of tumours, several compounds have been (or are currently being) evaluated in sarcoma patients. Finally, we discuss some of the reasons that could explain why, in some cases, encouraging preclinical data turned into disappointing results in the clinical setting.

Keywords